公开(公告)号：US09725474B2

公开(公告)日：2017-08-08

申请号：US14439460

申请日：2013-10-30

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Shumpei Murata ,  Shinichi Masada ,  Naoki Miyamoto ,  Tadashi Umemoto

IPC: C07F9/6561 ,  C07H21/02 ,  C07F9/6558 ,  C07H21/00 ,  C07D239/54 ,  C07D473/34 ,  C07F9/6512

CPC classification number: C07F9/65616 ,  C07D239/54 ,  C07D473/34 ,  C07F9/6512 ,  C07F9/65583 ,  C07F9/65586 ,  C07H21/00 ,  C07H21/02

Abstract: Provided is an oligonucleic acid analog which contains, as at least one structural unit thereof, a modified nucleic acid monomer compound which is a ring-open nucleoside having a cleaved carbon-carbon bond between the 2′ and 3′ positions and a substituent hydroxymethyl group at the 4′ position. When used as siRNA, the oligonucleic acid analog exhibits superior biological stability and target gene expression inhibiting activity. The oligonucleic acid analog can be used in antisense methods, ribozyme methods, and decoy methods, etc., can be used as a nucleic acid aptamer, and can also be used as a nucleic acid probe or molecular beacon, etc., or in genetic diagnostics, etc.

公开(公告)号：US12091410B2

公开(公告)日：2024-09-17

申请号：US17413473

申请日：2019-12-11

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Yuichi Kajita ,  Yuhei Miyanohana ,  Tatsuki Koike ,  Yasutaka Hoashi ,  Yasushi Hattori ,  Norihito Tokunaga ,  Tsuneo Oda ,  Tohru Miyazaki ,  Dilhumar Uyghur ,  Yoshiteru Ito ,  Kohei Takeuchi ,  Keisuke Imamura ,  Takahiro Sugimoto ,  Koichiro Fukuda ,  Yasuhisa Kohara ,  Rei Okamoto ,  Taiichi Ohra ,  Naoki Miyamoto ,  Yoshito Terao ,  Masanori Kawasaki

IPC: C07D471/04 ,  C07D215/38 ,  C07D231/56 ,  C07D277/64 ,  C07D401/14

CPC classification number: C07D471/04 ,  C07D215/38 ,  C07D231/56 ,  C07D277/64 ,  C07D401/14

Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity.
A compound represented by the formula (I):




wherein each symbol is as described in the description, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.

公开(公告)号：US12071434B2

公开(公告)日：2024-08-27

申请号：US17413469

申请日：2019-12-11

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Yuhei Miyanohana ,  Yuichi Kajita ,  Tatsuki Koike ,  Yasutaka Hoashi ,  Yasushi Hattori ,  Norihito Tokunaga ,  Tsuneo Oda ,  Tohru Miyazaki ,  Dilhumar Uyghur ,  Yoshiteru Ito ,  Kohei Takeuchi ,  Keisuke Imamura ,  Takahiro Sugimoto ,  Koichiro Fukuda ,  Yasuhisa Kohara ,  Rei Okamoto ,  Taiichi Ohra ,  Naoki Miyamoto ,  Jun Chiba ,  Yoshito Terao ,  Masanori Kawasaki

IPC: C07D455/02 ,  A61P25/26 ,  C07D217/24 ,  C07D237/32 ,  C07D239/90 ,  C07D401/06 ,  C07D401/10 ,  C07D403/10 ,  C07D417/06 ,  C07D471/04 ,  C07D498/04

CPC classification number: C07D455/02 ,  A61P25/26 ,  C07D217/24 ,  C07D237/32 ,  C07D239/90 ,  C07D401/06 ,  C07D401/10 ,  C07D403/10 ,  C07D417/06 ,  C07D471/04 ,  C07D498/04 ,  C07B2200/05

Abstract: The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity.
A compound represented by the formula (I):




wherein each symbol is as described in the description, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.